Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:ARGSQNASDAQ:BPTSYOTCMKTS:PPCBNASDAQ:SYRS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARGSQArgos Therapeutics$0.05$0.05$0.02▼$0.25$572K2.4713,394 shsN/ABPTSYBiophytis$1.38$2.34$1.38▼$8.00$484K0.842,149 shsN/APPCBPropanc Biopharma$5.10-36.3%$4.42$1.25▼$145.46$97K2.231,399 shs282 shsSYRSSyros Pharmaceuticals$0.02-1.3%$0.03$0.02▼$6.93$590K1.318.09 million shs207,839 shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARGSQArgos Therapeutics0.00%0.00%0.00%0.00%0.00%BPTSYBiophytis0.00%-20.23%-33.65%-58.93%-76.69%PPCBPropanc Biopharma0.00%+20.48%+173.50%+18.52%+499,900.00%SYRSSyros Pharmaceuticals0.00%-12.55%-36.83%-74.01%-99.63%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationARGSQArgos TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ABPTSYBiophytisN/AN/AN/AN/AN/AN/AN/AN/APPCBPropanc BiopharmaN/AN/AN/AN/AN/AN/AN/AN/ASYRSSyros Pharmaceuticals3.7291 of 5 stars3.13.00.04.30.02.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARGSQArgos Therapeutics 0.00N/AN/AN/ABPTSYBiophytis 0.00N/AN/AN/APPCBPropanc Biopharma 0.00N/AN/AN/ASYRSSyros Pharmaceuticals 2.20Hold$3.3315,051.52% UpsideCurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARGSQArgos Therapeutics$1.90M0.30N/AN/A($1.63) per share-0.03BPTSYBiophytisN/AN/AN/AN/A($16.18) per shareN/APPCBPropanc BiopharmaN/AN/AN/AN/A($0.01) per shareN/ASYRSSyros Pharmaceuticals$386K1.53N/AN/A$0.79 per share0.03Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARGSQArgos Therapeutics-$40.57MN/A0.00∞N/AN/AN/AN/AN/ABPTSYBiophytis-$18.43MN/A0.00∞N/AN/AN/AN/AN/APPCBPropanc Biopharma-$1.82MN/A0.00∞N/AN/AN/A-1,756.61%N/ASYRSSyros Pharmaceuticals-$164.57M-$3.03N/AN/AN/AN/A-3,369.56%-97.04%7/29/2025 (Estimated)Latest PPCB, SYRS, ARGSQ, and BPTSY EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q3 2025PPCBPropanc BiopharmaN/A-$12.50N/A-$12.50N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthARGSQArgos TherapeuticsN/AN/AN/AN/AN/ABPTSYBiophytisN/AN/AN/AN/AN/APPCBPropanc BiopharmaN/AN/AN/AN/AN/ASYRSSyros PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARGSQArgos TherapeuticsN/AN/AN/ABPTSYBiophytisN/A0.41N/APPCBPropanc BiopharmaN/A0.010.01SYRSSyros PharmaceuticalsN/A2.252.25Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARGSQArgos TherapeuticsN/ABPTSYBiophytis0.05%PPCBPropanc BiopharmaN/ASYRSSyros Pharmaceuticals91.47%Insider OwnershipCompanyInsider OwnershipARGSQArgos Therapeutics28.21%BPTSYBiophytis3.70%PPCBPropanc Biopharma0.10%SYRSSyros Pharmaceuticals12.26%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARGSQArgos Therapeutics12210.59 millionN/ANot OptionableBPTSYBiophytis30351,000338,000N/APPCBPropanc Biopharma119,000869.58 millionNot OptionableSYRSSyros Pharmaceuticals12026.83 million23.54 millionOptionablePPCB, SYRS, ARGSQ, and BPTSY HeadlinesRecent News About These CompaniesRege Nephro buys Tamibarotene-related assets from Syros PharmaceuticalsApril 15, 2025 | msn.comSyros Pharmaceuticals trading resumesMarch 1, 2025 | markets.businessinsider.comSyros Pharmaceuticals Plans to Wind Down OperationsMarch 1, 2025 | marketwatch.comSyros Pharmaceuticals voluntarily delists from Nasdaq, deregisters common stockMarch 1, 2025 | markets.businessinsider.comSyros Announces Voluntary Delisting from Nasdaq and SEC DeregistrationFebruary 28, 2025 | businesswire.comSyros Pharmaceuticals stock hits 52-week low at $0.18 amid steep declineJanuary 30, 2025 | msn.comSyros Pharmaceuticals Inc (SYRS) Stock Price Reaches $0.22: What Factors Are Influencing This Level?January 18, 2025 | bovnews.comWhat’s Causing Syros Pharmaceuticals Inc (SYRS) Stock’s -96.35% Drop Over the Last Six Months?January 16, 2025 | bovnews.comSYRS’s Latest Surge: What’s Behind the Spike?January 6, 2025 | bovnews.comThe SYRS Conundrum: Why Syros Pharmaceuticals Inc’s Stock Is Making Headlines AgainJanuary 2, 2025 | bovnews.comAnalysts Predict a $15 Target for Syros Pharmaceuticals Inc (SYRS) Stock—What Could Drive It There?December 31, 2024 | bovnews.comSyros Pharmaceuticals Inc (SYRS) Stock: More Resilient Than It AppearsDecember 27, 2024 | bovnews.comSyros Pharmaceuticals Inc (SYRS) Stock Dive: The Hidden Causes RevealedDecember 26, 2024 | bovnews.comWhat’s Fueling Syros Pharmaceuticals Inc (SYRS) Stock’s -94.59% Loss Below Its 200-Day SMA?December 14, 2024 | bovnews.comSyros Pharmaceuticals Inc (SYRS) Stock Settles at $0.24: What’s Contributing to This Price Point?December 7, 2024 | bovnews.comWhy Did Syros Pharmaceuticals Inc (SYRS) Stock Plunge -1.67% Last Week?December 5, 2024 | bovnews.comNancy A. Simonian Sells 37,070 Shares of Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) StockDecember 5, 2024 | insidertrades.comSyros Pharmaceuticals Inc (SYRS) Stock Rated Buy by H.C. WainwrightDecember 2, 2024 | bovnews.comWhy Is Syros Pharmaceuticals Inc (SYRS) Stock Lagging Behind -84.72% from Its 50-Day SMA?November 29, 2024 | bovnews.comSyros Pharmaceuticals, Inc. (NASDAQ:SYRS) Director Sells $36,372.51 in StockNovember 28, 2024 | insidertrades.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePPCB, SYRS, ARGSQ, and BPTSY Company DescriptionsArgos Therapeutics OTCMKTS:ARGSQ$0.05 0.00 (0.00%) As of 10/10/2019Argos Therapeutics, Inc., an immuno-oncology company, focuses on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases in North America. The company develops immunotherapies based on its proprietary technology platform, Arcelis. Its product candidates include rocapuldencel-T, which is in Phase III clinical trial for the treatment of metastatic renal cell carcinoma. The company also develops AGS-004, which is in Phase II clinical trials for the treatment of human immunodeficiency virus. The company was formerly known as Merix Bioscience, Inc. and changed its name to Argos Therapeutics, Inc. in October 2004. Argos Therapeutics, Inc. was founded in 1997 and is based in Durham, North Carolina. On November 30, 2018, Argos Therapeutics, Inc. filed a voluntary petition for reorganization under Chapter 11 in the US Bankruptcy Court for the District of Delaware.Biophytis NASDAQ:BPTSY$1.38 0.00 (0.00%) As of 06/13/2025Biophytis S.A., a clinical-stage biotechnology company, focuses on the development of therapeutics that slow the degenerative processes and improve functional outcomes for patients suffering from age-related diseases. Its therapeutics focuses on targeting and activating key biological resilience pathways that could protect against and counteract the effects of the multiple biological and environmental stresses including inflammatory, oxidative, metabolic, and viral stresses that lead to age-related diseases. The company's lead drug candidate is Sarconeos (BIO101), an orally administered small molecule in development for the treatment of neuromuscular diseases, including sarcopenia and Duchenne muscular dystrophy (DMD), as well as in Phase 2/3 clinical study for the treatment of severe respiratory failure in patients suffering from COVID-19. It also develops Macuneos (BIO201), an orally administered small molecule for the treatment of retinal diseases, including dry age-related macular degeneration (AMD) and Stargardt disease. Biophytis SA has a collaboration agreement with AFM-Telethon for the development of its Sarconeos (BIO101) for the treatment of DMD. The company was incorporated in 2006 and is headquartered in Paris, France.Propanc Biopharma OTCMKTS:PPCB$5.10 -2.90 (-36.25%) As of 11:16 AM EasternPropanc Biopharma, Inc., a biopharmaceutical company, develops cancer treatments for patients with pancreatic, ovarian, and colorectal cancer in Australia. It offers PRP, a formulation lead product that is in preclinical phase of development designed to enhance the anti-cancer effects of multiple enzymes. The company has a research collaboration with University of Jaén that undertakes the research activities for POP1 joint drug discovery program; and a joint research and drug discovery program with Universities of Jaén and Granada to investigate the changes in genetic and protein expression that occur in cancer cells. The company was formerly known as Propanc Health Group Corporation and changed its name to Propanc Biopharma, Inc. in April 2017. Propanc Biopharma, Inc. was incorporated in 2007 and is based in Camberwell, Australia.Syros Pharmaceuticals NASDAQ:SYRS$0.02 0.00 (-1.35%) As of 03:57 PM EasternSyros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was incorporated in 2011 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas New Catalysts to Drive NVIDIA’s Stock Price Even Higher Palantir Defies Bears, Leads S&P 500 in 2025 AST SpaceMobile’s Star Is Rising: Get in While It’s Still Cheap! Could Meta and Eli Lilly Trigger the Next Stock Split Boom? Iran Conflict Fuels Fertilizer Stocks’ Bullish Setup Is D-Wave's Latest $400M Sales Agreement a Dilution Deal-Breaker? Why Analysts Are Bullish on Celsius Stock After 30% Drop 3 Stocks With Rising Dividends Investors Shouldn’t Ignore Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
